Ambien CR(TM) is showing strong resistance to the presence of Ambien(R) IR generics, with third-quarter net sales reaching $176 million in the United States. Net sales of Ambien CR(TM) for the nine months to end September 2007 totaled $561 million. As expected, net sales of Ambien(R) IR, which went off patent in the United States on April 20, 2007, fell significantly in the third quarter to euro 35 million, versus euro 352 million in the comparable period of 2006.
In Japan, sales of Myslee(R) (not consolidated by sanofi-aventis) rose by 8.7% in the third quarter to euro 29 million. Over the 9 months to end September, the product reported 11.2% growth, to euro 84 million.
In the United States, Eloxatin(R), the market-leading colorectal cancer treatment as adjuvant and in the metastatic phase, recorded net sales growth of 12.3% to euro 247 million. In Europe, the introduction of Eloxatin(R) generics is continuing, with several countries now affected including Germany, the United Kingdom, Italy, Spain and France. European sales of the product fell by 38.6% in the third quarter to euro 89 million. In the "Other countries" region, Eloxatin(R) recorded a fine performance, with net sales up 30.6% at euro 47 million.
Third-quarter net sales of Tritace(R) were down 25.3% at euro 168 million, reflecting the introduction of generics of the product in Canada.
Net sales of Acomplia(R) were euro 21 million in the third quarter and
euro 58 million to end September. Results from clinical trials have shown
that Acomplia(R) has a powerful effect in reducing HbA1c that is comparable
with oral anti-diabetics. In addition, this effect is sustainable and
associated with weight loss. Sanofi-aventis has decided to substantially
broaden the ongoing development program in type 2 diabetes, which will
include more than 5,70
Copyright©2007 PR Newswire.
All rights reserved